Childress Capital Advisors LLC Grows Position in Gilead Sciences, Inc. $GILD

Childress Capital Advisors LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 68.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,764 shares of the biopharmaceutical company’s stock after purchasing an additional 5,190 shares during the quarter. Childress Capital Advisors LLC’s holdings in Gilead Sciences were worth $1,417,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Gilead Sciences during the second quarter valued at about $2,150,268,000. Ameriprise Financial Inc. increased its holdings in Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the last quarter. Invesco Ltd. raised its position in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. lifted its stake in Gilead Sciences by 164.4% during the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after purchasing an additional 2,169,266 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new position in shares of Gilead Sciences during the second quarter worth $238,083,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on GILD. Citigroup boosted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research note on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $131.68.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the insider directly owned 106,221 shares of the company’s stock, valued at $12,958,962. The trade was a 2.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00. Following the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $70,740,911.34. This represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

GILD stock opened at $121.36 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market capitalization of $150.57 billion, a P/E ratio of 18.82, a P/E/G ratio of 0.63 and a beta of 0.33. The business’s 50-day moving average is $123.08 and its two-hundred day moving average is $117.34. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.